FA
JSPR icon

Forefront Analytics’s Jasper Therapeutics JSPR Stock Holding History

Forefront Analytics’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,079
Closed -$77.6K – 69
2023
Q3 		$77.6K Buy
11,079
+4,142
+60% +$50.5K 0.04% 57
2023
Q2 		$95K Buy
6,937
+3,908
+129% +$58.1K 0.05% 56
2023
Q1 		$54.8K Sell
3,029
-8,371
-73% -$155K 0.03% 71
2022
Q4 		$55.1K Sell
11,400
-580
-5% -$3.88K 0.03% 68
2022
Q3 		$94K Buy
11,980
+8,517
+246% +$156K 0.05% 53
2022
Q2 		$69K Buy
3,463
+208
+6% +$5.92K 0.03% 57
2022
Q1 		$118K Buy
+3,255
New +$147K 0.04% 60

Other funds holding JSPR

ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Forefront Analytics's JSPR Position: Q4 2023 in Review

Forefront Analytics sold out of Jasper Therapeutics (JSPR) in Q4 2023, closing a stake of 11,079 shares — an estimated $77.6K sold.

Forefront Analytics first reported a position in JSPR in Q1 2022 and held it in 7 quarters. The position peaked at $118K in Q1 2022. 41 funds tracked by Wall St. Rank hold JSPR as of Q4 2023.

  • Forefront Analytics reported no remaining Jasper Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Forefront Analytics sold 11,079 Jasper Therapeutics shares in Q4 2023, an estimated $77.6K.
  • Forefront Analytics first reported a position in Jasper Therapeutics in Q1 2022 and held it in 7 quarters.
  • Forefront Analytics's Jasper Therapeutics position peaked at $118K in Q1 2022.
  • 41 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2023.

Based on Forefront Analytics's 13F filing for Q4 2023, filed 14 Feb 2024.